Iq-ai Dividends - IQAI

Iq-ai Dividends - IQAI

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Iq-ai Limited IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change Price Change % Stock Price Low Price High Price Open Price Close Price Last Trade
-0.05 -1.75% 2.80 2.80 2.85 2.85 2.85 11:04:55
more quote information »
Industry Sector
GENERAL RETAILERS

Iq-ai IQAI Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
10/03/2011FinalGBX0.831/12/200931/12/201006/04/201108/04/201105/05/20112.4
11/08/2010InterimGBX1.631/12/200931/12/201018/08/201020/08/201024/09/20100

Top Dividend Posts

DateSubject
18/3/2020
15:14
onceatrader: Giulia Bottaro 15:04 Wed 18 Mar 2020 [...] IQAI 12 month price target expects IQ-AI Ltd share price to rise to 63.25 in the next year from the last price of 2.10. +2,911.9% HTTP://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=FBDU:LSE
14/9/2019
15:01
hedgehog 100: There are two things in particular which could stimulate a bid for IQAI: • A weaker sterling makes a takeover of IQAI cheaper for foreign predators, as they will get more sterling for their own currency. • FDA approval is lengthy and costly, and achievement of it significantly derisks an investment. So after FDA approval for StoneChecker software, combined with Imaging Biometrics' existing FDA-approved products, IQAI could be a very attractive takeover target. To succeed though, I would think that an early bid would have to be at 20p or more, in order to get Trevor Brown and David Smith to agree to it. TB holds nearly 30% of IQAI, and DS sold his last company for 178 million dollars (Tenaxix Medical, in April 2014 ... after it had gained FDA approval for its product in 2013). At just 5.45p, IQAI's massive advances over the last twelve months, e.g. the Cortechs deal, the breakthrough on gadolinium-free imaging, and the $2.75M. US government grant, have yet to be really reflected in the share price, which has largely just returned to a similar level to previously. And that's even before the upside from FDA approval for StoneChecker software, and the stream of positive newsflow that is likely to be unleashed by that.
18/8/2019
13:15
hedgehog 100: Spurs, Thanks for that reminder of Imaging Biometrics' recent clinical trials success with its dT1 brain tumour scanning software (which wasn't actually RNSed). These are the most key points: "CONCLUSIONS: This study shows that dT1 can predict early progression comparable with the standard method but offers the potential for substantial time and cost savings for clinical trials." "Consequently, the dT1 tool has the potential to cause a paradigm shift in how brain tumor burden is assessed." HTTP://www.ajnr.org/content/40/7/1132 As I said at the time (in post 1448 above, on 8th. July): "It shows that we have disruptive technology at its very best." In addition, last December IQAI RNSed about success with this technology in a UK installation: 11/12/2018 07:00 UK Regulatory (RNS & others) IQ-AI Limited Installation at Barrow Neurological Institute " ... David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well." "Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow. ... " https://uk.advfn.com/stock-market/london/iq-ai-IQAI/share-news/IQ-AI-Limited-Installation-at-Barrow-Neurological/78859229 And the dT1 tool is one of IQAI's projects that will be accelerated with the new 6th. August 2019 placing funds: "The funds raised will be used to accelerate the commercialisation and development of two of Imaging Biometric's ("IB") projects: the low-flip angle technique; and IB's Delta T1 mapping approach." https://uk.advfn.com/stock-market/london/iq-ai-IQAI/share-news/IQ-AI-Limited-Completion-of-Placing-and-Conversion/80476823 In fact, David Smith has said (in an investor lunch last August) that whilst StoneChecker software has great potential, the real winner could be the brain scanning software of IB, which should be extended to other areas. Liver was mentioned as achievable with minor tweaks. Considering the immense potential for StoneChecker software, this is really saying something. A look at the Imaging Biometrics website shows how outstanding their technology is. HTTP://www.imagingbiometrics.com/ Indeed IQAI is a technology leader. It's groundbreaking products are disruptive technology at its finest, offering improved performance and big savings. And the high technological and other barriers to entry make it difficult to compete against. Allied to the brilliant business and sales nous of Trevor Brown and David Smith, and it's the perfect combination for a tip top growth stock.
20/7/2019
16:12
hedgehog 100: Thanks to Kiwi on LSE for posting this article on Wednesday - "Kidney Stone Management Devices Market to Reach US$ 1,500 Million by 2028; Global Sales Likely to Surpass 1 Million Units, Reveals Fact.MR PRESS RELEASE PR Newswire Sep. 20, 2018, 06:30 AM HTTP://markets.businessinsider.com/news/stocks/kidney-stone-management-devices-market-to-reach-us-1-500-million-by-2028-global-sales-likely-to-surpass-1-million-units-reveals-fact-mr-1027550530 There are more than 7,200 hospitals in the US alone, so the potential market is vast. IQAI's StoneChecker software product could generate a multi million pound stream of annually recurring revenue, at juicy margins. And this is just one of IQAI's multiple products, some of which have even greater potential than StoneChecker. IQAI is a technology leader. It's groundbreaking products are disruptive technology at its finest, offering improved performance and big savings. And the high technological and other barriers to entry make it difficult to compete against. Allied to the brilliant business and sales nous of Trevor Brown and David Smith, and it's the perfect combination for a tip top growth stock. FDA approval is lengthy and costly (IQAI's original submission of StoneChecker software was in May 2018), and achievement of it significantly derisks an investment. So afterwards, IQAI could be a very attractive takeover target. This could also partly be behind the big block buying that's been taking place. To succeed though, I would think that an early bid would have to be at 20p or more, in order to get Trevor Brown and David Smith to agree to it. TB holds nearly 30% of IQAI, and DS sold his last company for 178 million dollars (Tenaxix Medical, in 2014). At just 4.55p, IQAI's massive advances over the last twelve months, e.g. the Cortechs deal, and the breakthrough on gadolinium-free imaging, have yet to be reflected in the share price, which has simply returned to its prior level. And that's even before the upside from FDA approval for StoneChecker software, and the stream of positive newsflow that is likely to be unleashed by that.
16/7/2019
19:45
hedgehog 100: Here's something that LR2 said a while ago on the Feedback thread ... about himself: LR2 25 Mar '19 - 23:57 - 603 of 1125 " ... Word of warning - I am often a poor judge of character..." https://uk.advfn.com/cmn/fbb/thread.php3?id=43460410&from=603 LR2 clearly has a grudge against Trevor Brown, who he blames for a fall in the Feedback (FDBK) share price, since he resigned as a FDBK director just over two years ago. But is he really angry at TB, or angry at himself? When TB resigned, the FDBK share price was nearly 4p; now it's 0.95p. 08/06/2017 13:11 UK Regulatory (RNS & others) Feedback PLC Directorate Change "Feedback plc (AIM: FDBK), the medical imaging software company, announces that Trevor Brown, has resigned as a Non-Executive Director of Feedback, with immediate effect ... Dr Alastair Riddell, Non-Executive Chairman, commented: "I should like to thank Trevor for his invaluable support of the Company following its readmission in 2014 which has enabled it to achieve substantial progress to date. ... Trevor Brown, said: " ... I have indicated to the board that I am preparing to enter into an orderly market agreement in respect of my substantial shareholding ..." " https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Directorate-Change/74957678 Over the eleven months following his resignation Trevor Brown gradually sold down his FDBK holding, passing below the 3% threshold a little over a year ago: 10/05/2018 09:27 UK Regulatory (RNS & others) Feedback PLC Holding(s) in Company https://uk.advfn.com/stock-market/london/feedback-FDBK/share-news/Feedback-PLC-Holdings-in-Company/77392086 I'm not saying that TB is an angel (and Even Warren Buffett has his critics), but he is a very successful businessman and investor. And you can't be as successful a businessman and investor as TB without annoying some people who aren't as successful as him (e.g. LR2). There is an enormous amount of stuff on the internet, some true and some not, but once something is out there, it stays out there. E.g. If people posts links to Elon's Musk's allegations about the diver currently sueing him for libel, that certainly doesn't 'prove' them. https://en.wikipedia.org/wiki/Elon_Musk#Media_coverage_and_Musk's_behavior FDBK generally performed very well over the period TB was a director there, but hasn't since he left. And with FDBK, TB bought low and sold high. And now with IQAI, TB has been buying low again, and seems to be building something very exciting. In my opinion it makes sense to follow a winner like TB. In addition, IQAI is not just about TB, as we know. Remember that IQAI's August 2018 appointment David Smith sold his last company for $178M., and compare that to the $22M. it raised from investors: 06/08/2018 07:00 UKRegulatory (RNS & others) https://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Appointment-of-CEO-to-the-Op/78009277 And that IQAI acquired US company Imaging Biometrics, complete with founding CEO, in March 2018. (For £440,000 in shares at 4p per share, and $68,134 cash.) - 13/03/2018 07:40 UK Regulatory (RNS & others) Flying Brands Limited Acquisition of https://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Acquisition-of-Imaging-Biome/76928771 This has demonstrated Trevor Brown's company-building abilities at Flying Brands / IQAI in two major ways.
20/6/2019
18:05
hedgehog 100: The AI market is revolutionary, and investors can't seem to get enough of it. Here's an interesting observation from the AI thread: tomboyb 25 Sep '17 - 16:42 - 32 of 138 "Thanks for the linkx CHAPS - Some interesting read and without doubt a big future ahead here for AI - Not may AI stocks out there however -" https://uk.advfn.com/cmn/fbb/thread.php3?id=41649376&from=32 Another British AI (artificial intelligence) stock, Blue Prism (PRSM), has soared to become become a billion pound market cap. since it floated at £48.5M. in April 2016. This is a sign on investor enthusiasm for AI stocks ... and of the lack of AI stocks to invest in. PRSM has nearly 20-bagged since it floated on AIM three years ago at 78p, to its current share price of 1,465p (market cap. £1,128M.) The company is also currently valued at twenty times its annual revenue of £55.2M., despite a pre-tax loss of £26M. Revenue growth is high though (up from £6.1M. at its IPO) ... as indeed it should be at IQAI: 24/01/2019 07:00 UK Regulatory (RNS & others) Blue Prism Group PLC Full Year Results for the Year 31 October 2018 " ... Group revenue increased 125% ..." https://uk.advfn.com/stock-market/london/blue-prism-PRSM/share-news/Blue-Prism-Group-PLC-Full-Year-Results-for-the-Yea/79108559 30/04/2019 16:06 Alliance News IQ-AI Shares Jump As It Expects Sales To Double In 2019 30/04/2019 12:00 UK Regulatory (RNS & others) IQ-AI Limited Publication of Annual Report " ... We expect sales for the full year 2019 to more than double those for 2018. The future looks to be an exciting place for IQ-AI...." https://uk.advfn.com/stock-market/london/iq-ai-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 Indeed IQAI's plan is to deliver revenues of $20M. to $30M. annual within the next few years on existing products but double that with 'planned' products. I.e. $60M. annual sales. Or £47.24M. at current exchange rates. (1 Pound sterling equals 1.27 United States Dollar.) Which isn't that far short of PRSM's current annual revenue of £55.2M. And in view of IQAI's David Smith's track record this plan has to be taken seriously. (He sold his last company for $178M., and before that played a leading role in driving sales at Biocompatibles from 0 to over £40M. Biocompatibles was acquired by BTG in 2010 for £177M.) IQAI isn't a smaller version of PRSM, which could be hard to compete against for a smaller company, but they are both strong AI plays. And they are both benefitting from the trend towards introducing their products. The meditech revolution is coming, and IQAI will be part of it. Right place, right time.
19/6/2019
15:49
hedgehog 100: The 'gang of four' top management at IQAI is a veritable dream team of talent and ability: Trevor Brown, CEO of IQAI HTTP://www.flyingbrands.co.uk/ David Smith, Chief Operating Officer and CEO of the group's two operating businesses, StoneChecker Software and Imaging Biometrics Nick Stevens, CEO of Stone Checker Software Ltd HTTP://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/ Michael Schmainda, CEO of Imaging Biometrics HTTP://www.imagingbiometrics.com/ And all four have invested significant sums into Flying Brands / IQAI within the last few/several months ... mostly at a price of 2p per share or more: 11/09/2018 07:01 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78229870 11/09/2018 09:00 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that Nick Stevens, CEO to Stone Checker Software Ltd, acquired 1,200,000 ordinary shares in the Company on 10 September 2018, representing 1% of the Company's issued share capital, at a price of 2.5 pence per share. Previously to this notification, Mr Stevens held 2,000,000 ordinary shares in the Company. Therefore Nick Steven's total shareholding represents 2.66% of the Company's issued share capital." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78231278 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 (IQAI's March 2019 fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p).) Trevor Brown also invested a further £250,000 into IQAI on 29th. May 2019, again at a massive premium to the pre-existing share price. I.e. the IAQI share price mid price at opening then was 1.1p; the fundraising was at 1.5p: i.e. a 26.7% premium. This sort of management 'cluster investment' into a share is a very bullish indicator, as it is a terrific vote of confidence in the company and its value.
17/6/2019
14:27
hedgehog 100: What happens to IQAI (the business and the share price) after the imminent FDA approval for IQAI's StoneChecker software: which should certainly be announced this month, and could be any day. The fact that FDA approval has taken so long shows how rigorous the process is, how advanced the product is, and also what a great achievement approval will be. And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology. This won't therefore be your 'average' good news: it will be gold-plated, company-transformative, 'talk of the town' news. Therefore, I think that we can expect a very big immediate rerating upwards in the share price ... but that should be just for starters. The general upward momentum could continue for weeks, months, and years. And in terms of business, IQAI is chaffing at the bit to start selling StoneChecker into the multi trillion dollar US healthcare market, and has been investing into its business ahead of that, a very positive sign. IQAI also appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received, if not earlier. - 08/02/2019 10:29 UKREG IQ-AI Limited Business Update "...Meanwhile IQ-AI continues to seek business development relationships that will expose its products to a broader audience worldwide. Several marketing and distribution alliances are under active consideration. These will be evaluated, and if appropriate, will be announced in the next few months...." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Business-Update/79217612 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report "... The Company will focus on four areas of revenue development in 2019: 1. Sales development of existing products During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 All this bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.
07/6/2019
13:49
hedgehog 100: What is far more important is what happens to IQAI (the business and the share price) after the imminent FDA approval for IQAI's StoneChecker software: which should be announced this month, and could be any day. The fact that FDA approval has taken so long shows how rigorous the process is, how advanced the product is, and also what a great achievement approval will be. And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology. This won't therefore be your 'average' good news: it will be gold-plated, company-transformative, 'talk of the town' news. Therefore, I think that we can expect a very big immediate rerating upwards in the share price ... but that should be just for starters. The general upward momentum could continue for weeks, months, and years. And in terms of business, IQAI is chaffing at the bit to start selling StoneChecker into the multi trillion dollar US healthcare market, and has been investing into its business ahead of that, a very positive sign. IQAI also appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received. - 08/02/2019 10:29 UKREG IQ-AI Limited Business Update "...Meanwhile IQ-AI continues to seek business development relationships that will expose its products to a broader audience worldwide. Several marketing and distribution alliances are under active consideration. These will be evaluated, and if appropriate, will be announced in the next few months...." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Business-Update/79217612 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report "... The Company will focus on four areas of revenue development in 2019: 1. Sales development of existing products During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 All this bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.
06/6/2019
21:05
lr2: Nice try picking out two NED positions held by Trevor Brown and then make a massive assumption that the share price of the company in each case reflected on Trevor being there. In case you forgot, a “non-executive” director is merely a director who is NOT involved in the day-to-day management of the company. Suggest you go back and do the same chart cut and paste on his last two CEO positions. In the meantime perhaps you could advise why the IQAI directors pay went from £50,500 in 2017 to £125,000 in the 2018 accounts? What had they done to earn that pay rise? Or why Trevor Brown said IQAI was fully funded until June '19 but ended up raising money in March '19? Or why Trevor Brown said FDA clearance was expected by end December '18 but we are still waiting for it today? Or why when Trevor Brown had already raised money in March '19 did he have to raise again two months later in May '19? Or why was the mistake in 29th May '19 RNS not noticed by either Trevor Brown, the IQAI board, or Peterhouse? Too chummy perhaps? Or why a Peterhouse Executive Director, Qu Li, sits on the 3 person board at IQAI? Do you not consider that a conflict of interest and the board designed to make Trevor Brown all powerful? Or why in June '17 Trevor Brown sold Stone Checker Software Ltd to IQAI for 4,000,000 IQAI shares at a 3p per share valuation? Who benefited from that? Trevor Brown with another 4 million shares or IQAI shareholders who took on a company which had, at last count, assets of £1,628 and debts of £213,518. Or why IQAI stated in their last accounts that revenue was accelerating but had revenue in the 1st half year of £126k and only revenue in the 2nd half year of £39k? How is £39k an acceleration from the previous £126k? Or what each resolution passed at today's AGM was actually about? There you go HH, a simple one to end with.
ADVFN Advertorial
Your Recent History
LSE
IQAI
Iq-ai
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200529 02:24:31